Timestamp/Notes from Conference Call that could be generating negative sentiment:
10:31 - Sales Growth is expected to be somewhat tempered during Thanksgiving and Holidays when patients postpone visits with their Doctors.
10:40 - Inventory levels held by distributors remained 1-2 weeks, although at the end of Q3 there was a slight increase in inventory days in relation to Q2.
16:40 - We were the beneficiary of a slight increase in distribution inventories this quarter
20:45 - Cost of Goods Sold % UP relative to Q2
21:50 - SGA Expense guided to UPPER range of $250M
23:00 - R&D Expense guided HIGHER
24:00 - Unreimbursed R&D guided HIGHER and will update in Jan, 2014
32:10 - Question regarding DSO and inventory levels - No real answer, just that it is competitive data, next caller.
Information is paraphrased from the call. Please listen to the call and arrive at your own conclusion.
Replay of the Q3 2013 conference call is available on the Regeneron website in the investors/events presentation section.
DNKN is going to $60+ in the near-term (6-12 mos); WAY higher $ in the long term. Only reason to watch DNKN stock price on a regular basis is to spot good entry points. DNKN is still in the early stages of expansion...
Panelists were asked whether a new trial should be conducted, but opinion was split. Some said a new trial was the only way to clear up the controversy, but others like Gerald van Belle, a professor at the University of Washington in Seattle, said it was too late.
“There are lots of other medications in the pipeline right now and that’s probably where the action will be,” he said.